首页> 外国专利> Chimeric Endocytic Receptors and Method of Use Thereof

Chimeric Endocytic Receptors and Method of Use Thereof

机译:嵌合内吞受体及其使用方法

摘要

The invention discloses chimeric endocytic receptor CER-based constructs for activating and regulating immune response, and method for using the same. The CER-based constructs are based on the structure of FcγRI/γ chain and incorporate high-affinity binding domain from receptors or antibodies shown to uptake specific antigen and present the antigen to T cells or B cells to initiate the antigen-specific immune response, Such design has the ability to transform native monocytes or T cells to CER-expressing monocytes (CER-M) or CER-expressing T cells (CER-T) in recognizing and uptake the target antigen and activate subsequent immune responses. Such engineered CER-M or CER-T can be used to treat tumor, viral diseases and autoimmune diseases directly. The endocytosis process with involvement of FcR-γ may enhance and coordinate T cell activation in combination with T cell activation by other types of constructs such as CAR.
机译:本发明公开了用于激活和调节免疫应答的基于嵌合内吞受体CER的构建体及其使用方法。基于CER的构建体基于FcγRI/γ链的结构,并结合了来自受体或抗体的高亲和力结合结构域,这些受体或抗体被证明会摄取特定抗原并将抗原呈递给T细胞或B细胞以启动抗原特异性免疫反应,这种设计具有将天然单核细胞或T细胞转化为表达CER的单核细胞(CER-M)或表达CER的T细胞(CER-T)的能力,以识别和摄取靶抗原并激活后续的免疫反应。这种工程化的CER-M或CER-T可直接用于治疗肿瘤,病毒性疾病和自身免疫性疾病。 FcR-γ参与的胞吞过程可增强和协调T细胞活化,并与其他类型的构建体(如CAR)活化T细胞结合。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号